Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

By                      

Experimental and Therapeutic Medicine, Vol. 2, Iss. 4, 2011-01 ,pp. : 685-693

Spandidos Publications

Access to resources Recommend Favorite

Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring

By Gatineau M.  

Targeted Oncology, Vol. 1, Iss. 3, 2006-07 ,pp. : 114-122

Springer Publishing Company

Access to resources Recommend Favorite

Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib

By                              

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 802-806

Science Publishers

Access to resources Recommend Favorite

Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 646-650

Bentham Science Publishers

Access to resources Recommend Favorite

Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib

By Kanazawa Shigenori   Yamaguchi Kazuyuki   Kinoshita Yoshimi   Komiyama Yutaka   Muramatsu Mikiko   Nomura Shosaku  

Journal of Cancer Research and Clinical Oncology, Vol. 132, Iss. 11, 2006-11 ,pp. : 719-725

Springer Publishing Company

Access to resources Recommend Favorite